 | Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial
msn.com - November 23 at 2:27 PM |
 | Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
finance.yahoo.com - November 23 at 9:25 AM |
 | Kevin C. Tang Sells 255,331 Shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock
americanbankingnews.com - November 22 at 8:10 PM |
| Kevin C. Tang Sells 369,533 Shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) Stock
americanbankingnews.com - November 22 at 8:10 PM |
| Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Increase in Short Interest
americanbankingnews.com - November 20 at 2:38 AM |
| Brokerages Expect Aptevo Therapeutics Inc. (NASDAQ:APVO) Will Post Quarterly Sales of $3.40 Million
americanbankingnews.com - November 18 at 2:28 AM |
 | Aptevo Therapeutics Announces Presentation Of 2 Abstracts At Upcoming American Society Of Hematology Annual Meeting
benzinga.com - November 16 at 7:43 PM |
| Zacks: Analysts Anticipate Aptevo Therapeutics Inc. (NASDAQ:APVO) Will Announce Earnings of -$1.41 Per Share
americanbankingnews.com - November 16 at 5:20 PM |
| Aptevo Therapeutics (NASDAQ:APVO) PT Lowered to $36.00 at Roth Capital
americanbankingnews.com - November 15 at 11:07 AM |
| Alligator Bioscience, Aptevo Therapeutics Announce Poster Presentation Of ALG.APV-527 At SITC Annual Meeting 2021
benzinga.com - November 13 at 1:39 PM |
| Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
finance.yahoo.com - November 12 at 9:46 AM |
|
| Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
finance.yahoo.com - November 11 at 6:10 PM |
| Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
finance.yahoo.com - November 11 at 1:10 PM |
| Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
finance.yahoo.com - October 27 at 10:32 AM |
| Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
finance.yahoo.com - October 26 at 9:14 AM |
| Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
finance.yahoo.com - September 28 at 10:07 AM |
| Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
finance.yahoo.com - August 17 at 3:57 PM |
| Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
finance.yahoo.com - August 12 at 4:10 PM |
| Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
finance.yahoo.com - July 16 at 10:20 AM |
 | Aptevo Therapeutics Announces Inclusion in the Russell Microcap Index
finanznachrichten.de - June 29 at 8:20 AM |
| Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
finance.yahoo.com - June 29 at 8:20 AM |
 | Aptevo CEO says Seattle biotech scene is 'robust and growing'
bizjournals.com - June 25 at 11:56 PM |
| Aptevo Therapeutics Insights: Return On Capital Employed
benzinga.com - June 18 at 12:53 PM |
| Looking Into Aptevo Therapeutics's Return On Capital Employed
benzinga.com - June 4 at 2:58 PM |
 | APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Regulation FD Disclosure
marketwatch.com - May 30 at 12:52 AM |
| Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
finance.yahoo.com - May 27 at 9:16 AM |
| Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients
finance.yahoo.com - May 26 at 3:42 PM |
| Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
finance.yahoo.com - May 26 at 10:26 AM |
| American Eagle Completes Magnetotelluric Survey at its Golden Trend Property in the Cortez, Nevada; Publishes Interview with CEO Anthony Moreau and VP of Exploration Mark Bradley
finance.yahoo.com - May 17 at 6:29 AM |
| Aptevo Therapeutics Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 11 at 10:16 AM |
| Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
finance.yahoo.com - April 9 at 2:11 PM |
| Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 31 at 9:22 AM |
|
| Aptevo Therapeutics: Aptevo Confirms Receipt of Nominations and Proposal Notice
finanznachrichten.de - February 9 at 9:29 PM |
| Aptevo Confirms Receipt of Nominations and Proposal Notice
finance.yahoo.com - February 9 at 9:29 PM |
| Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why
finance.yahoo.com - January 6 at 2:34 PM |
| Kaskela Law LLC Announces Investigation of Aptevo Therapeutics Inc. (APVO) and Encourages Shareholders to Contact the Firm
finance.yahoo.com - December 19 at 6:47 PM |
| Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442
finance.yahoo.com - December 2 at 10:01 AM |
| Aptevo Therapeutics: Aptevo Confirms Receipt of Unsolicited Indication of Interest
finanznachrichten.de - November 21 at 10:28 PM |
| Aptevo Confirms Receipt of Unsolicited Indication of Interest
finance.yahoo.com - November 19 at 6:43 PM |
 | Aptevo gets $50/share takeout offer from shareholder Tang
seekingalpha.com - November 18 at 10:30 PM |
 | Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
nasdaq.com - November 16 at 12:19 PM |
| Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development
finance.yahoo.com - November 16 at 12:19 PM |
| Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update
benzinga.com - November 10 at 6:44 PM |
| Aptevo's lead drug achieves second remission in early-stage study
seekingalpha.com - November 9 at 1:37 PM |
| Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting
finance.yahoo.com - November 9 at 1:37 PM |
| 28 Stocks Moving in Monday's Pre-Market Session
msn.com - November 9 at 8:37 AM |
| Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake
seekingalpha.com - November 9 at 8:37 AM |
| Aptevo's lead drug achieves second remission in early-stage blood cancer study
seekingalpha.com - November 9 at 8:37 AM |
| Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
finance.yahoo.com - November 9 at 8:36 AM |
| Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan
finance.yahoo.com - November 9 at 12:06 AM |
